Craig Monger

Craig Monger

Auto-generated profile, based on publicly available information

Craig Monger

Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Nature Genetics
Verified
Journal Article
Closed access
GBGerard L. Brien
Gerard L. Brien
RBRaul Bardini Bressan
Raul Bardini Bressan
CMCraig Monger
Craig Monger
DGDáire Gannon
Dáire Gannon
ELEimear Lagan
Eimear Lagan
ABAdrian P. Bracken
Adrian P. Bracken

28 April 2020 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
ITIoanna Tzani
Ioanna Tzani
CMCraig Monger
Craig Monger
KMKrishna Motheramgari
Krishna Motheramgari
CGClair Gallagher
Clair Gallagher
RHRyan Hagan
Ryan Hagan
CCColin Clarke
Colin Clarke

27 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAnthony M. Doherty
Anthony M. Doherty
ELEimear Lagan
Eimear Lagan
RERichard Elliott
Richard Elliott
KWKeiran Wynne
Keiran Wynne
CMCraig Monger
Craig Monger
GBGerard L. Brien
Gerard L. Brien
SUMMARY: Synovial sarcoma is driven by the SS18-SSX fusion oncoprotein, which has been assumed to promote tumorigenesis through its incorporation into the SWI/SNF chromatin remodeling complexes. Accordingly, therapeutic efforts have focused on targeting SS18-SSX containing SWI/SNF assemblies, yet these approaches have produced limited clinical benefit. Here, we demonstrate that SS18-SSX sustains oncogenic transcription independent of SWI/SNF activity. Despite efficient degradation and dismantling of SWI/SNF complexes, fusion occupancy at target loci and associated gene expression programs remain largely intact. Instead, we identify the acetyltransferase P300 as an essential co-factor supporting SS18-SSX chromatin binding and transcriptional activation. Targeting P300 displaces the fusion from chromatin, suppresses its transcriptional output, compromising synovial sarcoma viability. Notably, dual PROTAC mediated degradation of P300 and SWI/SNF produces strong synergistic effects, broadly disrupting SS18-SSX localization and function. These findings redefine the mechanistic basis of synovial sarcoma and reveal a mechanistically anchored therapeutic strategy for targeting its core oncogenic driver.

15 October 2025 in bioRxiv
Verified
Preprint
Open access
DADaniel Angelov
Daniel Angelov
JNJames Nolan
James Nolan
GHGrainne Holland
Grainne Holland
DNDarragh Nimmo
Darragh Nimmo
MDMolly Davies
Molly Davies
ABAdrian P. Bracken
Adrian P. Bracken
SUMMARY: The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. EZH2 inhibitors provide clinical benefit, but resistance frequently develops, highlighting the need for alternative therapeutic targets. Here, we identify the PRC2 accessory protein AEBP2 as a specific genetic dependency in EZH2-mutant DLBCL. While AEBP2 acts through PRC2, its essential role is surprisingly independent of canonical H3K27me3-mediated gene silencing. Instead, AEBP2 functions within a PRC2.2 complex lacking JARID2, using its zinc-finger domains to sample intergenic chromatin to sustain H3K27me2. Notably, loss of AEBP2 or NSD2 caused contrasting changes in intergenic H3K27me2 levels, driving sensitivity or resistance to PRC2 inhibitors, respectively. Our findings identify AEBP2-PRC2.2-maintained intergenic H3K27me2 as a therapeutic vulnerability in EZH2-mutant DLBCL and highlight dysregulated H3K27me2 as an underappreciated form of PRC2 dysfunction in cancer, with important therapeutic implications.